Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

Stepen Smith; John W. Sweetenham

doi:10.2217/14796694.3.3.255

Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

Stepen Smith, John W. Sweetenham

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

Original language	English (US)
Pages (from-to)	255-262
Number of pages	8
Journal	Future Oncology
Volume	3
Issue number	3
DOIs	https://doi.org/10.2217/14796694.3.3.255
State	Published - Jun 1 2007
Externally published	Yes

Keywords

Bexxar®
I131
Indolent NHL
Radioimmunoconjugate
Tositumomab

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/14796694.3.3.255

Cite this

@article{10b187b3dfe448dd844eaa90a143393d,

title = "Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma",

abstract = "Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.",

keywords = "Bexxar{\textregistered}, I131, Indolent NHL, Radioimmunoconjugate, Tositumomab",

author = "Stepen Smith and Sweetenham, {John W.}",

year = "2007",

month = jun,

day = "1",

doi = "10.2217/14796694.3.3.255",

language = "English (US)",

volume = "3",

pages = "255--262",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

AU - Smith, Stepen

AU - Sweetenham, John W.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

AB - Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

KW - Bexxar®

KW - I131

KW - Indolent NHL

KW - Radioimmunoconjugate

KW - Tositumomab

UR - http://www.scopus.com/inward/record.url?scp=34347371248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347371248&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.3.255

DO - 10.2217/14796694.3.3.255

M3 - Article

C2 - 17547519

AN - SCOPUS:34347371248

SN - 1479-6694

VL - 3

SP - 255

EP - 262

JO - Future Oncology

JF - Future Oncology

IS - 3

ER -

Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this